Media Room
Latest Press Releases
Last Update: January 11, 2010
- May 27, 2010 - Data Published in “Nature” Confirms Development of APG101 to Treat Cancer
- January 11, 2010 - Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
- November 16, 2009 - Apogenix Receives Orphan Drug Designation for APG101 in the US and Positive Opinion on Orphan Product Designation in Europe
- October 27, 2009 - Apogenix Significantly Strengthens IP Protection for its Clinical Lead Compound APG101
- July 29, 2009 - Apogenix Receives Research Grants of € 2 600 000 as Partner of the Biotechnology Cluster Rhine-Neckar
Press Kit
The press kit contains:
- current company presentation
- latest press releases
- company logo & images
Press Contact
Oliver Schlüter, Ph.D - Director of Finance - Apogenix GmbH
Phonework: +49 (0) 6221 58608 0
E-mail: oliver.schlueter@apogenix.com
